Table 2

Donor and transplant recipient demographic and clinical characteristics

All (n = 253)CR1 (n = 183)CR2 (n = 70)P*
Donor type, n (%)NS
 Related83 (32.8%)62 (33.9%)21 (30.0%)
 Unrelated170 (67.2%)121 (66.1%)49 (70.0%)
Median donor age (range), y38.7 (5.7-77.8)39.1 (5.7-67.4)37.6 (10.6-77.8)NS
Donor gender, n (%)NS
 Male125 (49.4%)96 (52.5%)29 (41.4%)
 Female109 (43.1%)72 (39.3%)37 (52.9%)
 Missing19 (7.5%)15 (8.2%)4 (5.7%)
Patient/donor gender, n (%)NS
 Male/male66 (26.1%)49 (26.8%)17 (24.3%)
 Female/female56 (22.1%)40 (21.9%)16 (22.9%)
 Male/female53 (21.0%)32 (17.5%)21 (30.0%)
 Female/male59 (23.3%)47 (25.7%)12 (17.1%)
 Missing19 (7.5%)15 (8.2%)4 (5.7%)
Conditioning regimen, n (%).001
 Bu/Cy ± ATG or CAMP65 (25.7%)57 (31.2%)8 (11.4%)
 Bu/Flu ± ATG34 (13.4%)24 (13.1%)10 (14.3%)
 H-TBI/Cy or H-TBI/TEPA/Flu72 (28.6%)48 (26.2%)24 (34.3%)
 Treo/Flu ± L-TBI68 (26.9%)49 (26.8%)19 (27.1%)
 Flu/radiolabeled Ab/L-TBI14 (5.5%)5 (2.7%)9 (12.9%)
Source of stem cells, n (%)NS
 PBSC136 (53.8%)99 (54.1%)37 (52.9%)
 BM75 (29.6%)56 (30.6%)19 (27.1%)
 Cord Blood42 (16.6%)28 (15.3%)14 (20.0%)
GVHD prophylaxisNS
 Calcineurin inhibitor + methotrexate170 (67.2%)129 (70.5%)41 (58.6%)
 Calcineurin inhibitor + MMF56 (22.1%)33 (18.0%)23 (32.9%)
 Cytoxan23 (9.1%)17 (9.3%)6 (8.6%)
 Other4 (1.6%)4 (2.2%)0 (0%)
  • Ab, antibody; ATG, antithymocyte globulin; BM, bone marrow; Bu, busulfan; CAMP, campath; Cy, cytoxan; Flu, fludarabine; H-TBI, high-dose TBI; L-TBI, low-dose TBI; MMF, mycophenolate mofetil; NS, not significant; PBSC, peripheral blood stem cells; TEPA, thiotepa.

  • * For the comparison CR1 vs CR2.